The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 6 of 6
Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…
Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial
This article from the Lancet HIV discusses the results of a secondary analysis of data from the HPTN 083 trial of cabotegravir for PrEP, looking specifically at the cohort of transgender women included in the study.
Same-day Initiation of Oral Pre-exposure Prophylaxis among Gay, Bisexual, and Other Cisgender Men who Have Sex with Men and Transgender Women in Brazil, Mexico, and Peru (ImPrEP): A prospective, single-arm, open-label, multicentre implementation study
This article from The Lancet HIV assesses the feasibility of same-day oral PrEP delivery amongst gay and bisexual men who have sex with men and transgender women in Brazil, Mexico, and Peru.
Transgender Women in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy interactions with long-acting cabotegravir
This poster from AIDS 2022 presents an analysis of results from the HPTN 083 study, looking at the impact of feminizing gender affirming hormones on cabotegravir (CAB) for PrEP pharmacokinetics.
Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study
This article from the Journal of the International AIDS Society assesses factors associated with long-term PrEP engagement and adherence among trans women enrolled in the Implementation of PrEP (ImPrEP) study, the largest PrEP demonstration study in Latin America.
Results from the HPTN 083 Trial
The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…